Immatics IMTX
NASDAQ IMTX
$7.59 -0.85 (-10.07%)
At close: Oct 2, 2026 · 4:00 PM EDT

Immatics (IMTX) Gains from Sales and Divestitures (2025 - 2026)

Updated

Immatics (IMTX) recorded Gains from Sales and Divestitures of $56,196 in Q1 2026, up 33.6% from $42,075 a year earlier.

Analysis

Immatics (IMTX) Gains from Sales and Divestitures (2025 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Immatics 1.02 Bn -1.02 Bn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 56,195.79
Sep 30, 2025 136,779.45
Mar 31, 2025 42,075.38
API Access

Immatics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=IMTX&period=max&api_key=YOUR_API_KEY